LEXX Lexaria Bioscience Corp.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1348362 · Fiscal year ends 08/31
Financial factors as of 2026-05-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-68.5%
TTM net income YoY32.1%
TTM EPS YoY50.0%
Revenue 3-yr CAGR-14.2%
Net income 3-yr CAGR—
Margins
Gross margin100.0%
Operating margin-3,973.2%
Net margin-3,985.6%
FCF margin-3,848.6%
EBITDA margin-3,960.4%
Returns
ROE-150.3%
ROA-134.2%
ROIC (approx.)-553.9%
Asset turnover0.03x
Leverage & solvency
Liabilities / assets9.1%
Debt / equity0.00x
Current ratio10.60x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue21.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-05-31 | 2026Q22026-02-28 | 2026Q12025-11-30 | 2025Q4*2025-08-31 | 2025Q32025-05-31 | 2025Q22025-02-28 | 2025Q12024-11-30 | 2024Q4*2024-08-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $20,000 | $0 | $174,000 | $174,000 | $174,000 | $183,923 | $84,000 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $2,720 | $0 |
| Gross profit | $0 | $20,000 | $0 | $174,000 | $174,000 | $174,000 | $181,203 | $84,000 |
| R&D expense | $970,834 | $475,388 | $671,340 | $1.88M | $2.72M | $1.69M | $1.95M | $967,206 |
| SG&A expense | $1.02M | $996,515 | $902,291 | $980,477 | $1.21M | $1.24M | $918,690 | $1.32M |
| Operating income | -$1.99M | -$1.45M | -$1.57M | -$2.69M | -$3.75M | -$2.75M | -$2.69M | -$2.20M |
| Pretax income | -$1.99M | — | — | -$2.70M | -$3.79M | — | — | — |
| Income tax | $14 | $2,598 | $1,791 | — | $0 | $0 | $0 | — |
| Net income | -$1.99M | -$1.45M | -$1.60M | -$2.70M | -$3.79M | -$2.71M | -$2.70M | -$2.18M |
| EBITDA | -$1.98M | -$1.44M | -$1.56M | -$2.70M | -$3.72M | -$2.75M | -$2.66M | -$2.19M |
| EPS (diluted) | -0.08 | -0.06 | -0.07 | — | -0.21 | -0.15 | -0.16 | — |
| Weighted avg. shares (diluted) | 24.81M | 24.44M | 21.38M | — | 18.30M | 17.51M | 16.67M | — |
| Banking | ||||||||
| Net interest income | — | — | — | — | — | — | — | $6,993 |
| Balance sheet | ||||||||
| Cash & equivalents | $3.50M | $5.10M | $4.30M | $1.80M | $4.59M | $6.47M | $8.08M | $6.50M |
| Short-term investments | $142,103 | $141,266 | $143,267 | $143,267 | $33,540 | $73,915 | $39,875 | $55,807 |
| Receivables | $48,998 | $42,029 | $88,044 | $368,358 | $358,129 | $331,166 | $263,491 | $154,477 |
| Current assets | $4.06M | $5.77M | $5.36M | $3.47M | $5.81M | $7.72M | $8.83M | $7.90M |
| PP&E, net | $229,017 | $242,931 | $216,120 | $228,129 | $240,139 | $261,890 | $270,621 | $254,709 |
| Intangibles | $339,016 | $318,058 | $308,060 | $307,818 | $516,420 | $506,180 | $505,373 | $516,676 |
| Total assets | $4.78M | $6.49M | $6.05M | $4.18M | $6.74M | $8.68M | $9.79M | $8.87M |
| Current liabilities | $383,412 | $214,671 | $1.46M | $1.49M | $1.49M | $1.82M | $297,798 | $1.10M |
| Total liabilities | $437,091 | $276,997 | $1.53M | $1.57M | $1.57M | $1.92M | $399,718 | $1.21M |
| Shareholders' equity | $4.74M | $6.60M | $4.91M | $2.99M | $5.55M | $7.14M | $9.77M | $8.04M |
| Shares outstanding | 24.79M | 24.89M | 22.23M | 19.56M | 19.46M | 17.45M | 17.45M | 19.56M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.64M | -$2.16M | -$984,098 | -$2.64M | -$3.58M | -$1.50M | -$2.73M | -$1.89M |
| Capital expenditure | $0 | $40,816 | $0 | $1 | -$1 | $1 | $24,645 | $43,014 |
| Free cash flow | -$1.64M | -$2.20M | -$984,098 | -$2.64M | -$3.58M | -$1.50M | -$2.75M | -$1.93M |
| Investing cash flow | -$27,089 | -$53,909 | -$5,099 | -$157,878 | -$19,443 | -$27,894 | -$37,804 | -$69,587 |
| Financing cash flow | $0 | $3.04M | $3.47M | $0 | $1.69M | $11,720 | $4.35M | $0 |
| Depreciation & amortization | $13,914 | $14,005 | $12,009 | -$15,202 | $30,955 | $2,277 | $33,195 | $16,370 |
| Stock-based compensation | $92,944 | $74,895 | $74,895 | $122,724 | $470,136 | $167,219 | $99,415 | $96,510 |
Free plan shows the latest 8 periods; Pro shows all 68 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.